CN109069442B - 异甘草酸或其盐的吸入制剂及其应用 - Google Patents

异甘草酸或其盐的吸入制剂及其应用 Download PDF

Info

Publication number
CN109069442B
CN109069442B CN201780018629.0A CN201780018629A CN109069442B CN 109069442 B CN109069442 B CN 109069442B CN 201780018629 A CN201780018629 A CN 201780018629A CN 109069442 B CN109069442 B CN 109069442B
Authority
CN
China
Prior art keywords
inhalation
use according
magnesium isoglycyrrhizinate
lactose
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780018629.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069442A (zh
Inventor
顾红梅
王善春
张喜全
黄磊
徐宏江
宋伟
董平
孙中英
张颖
陈德洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202010842414.4A priority Critical patent/CN111920785B/zh
Publication of CN109069442A publication Critical patent/CN109069442A/zh
Application granted granted Critical
Publication of CN109069442B publication Critical patent/CN109069442B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780018629.0A 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用 Active CN109069442B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010842414.4A CN111920785B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610237175 2016-04-15
CN2016102371753 2016-04-15
PCT/CN2017/080583 WO2017177966A1 (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其在制备治疗呼吸系统疾病药物中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010842414.4A Division CN111920785B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用

Publications (2)

Publication Number Publication Date
CN109069442A CN109069442A (zh) 2018-12-21
CN109069442B true CN109069442B (zh) 2020-09-04

Family

ID=60042326

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010842414.4A Active CN111920785B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用
CN201780018629.0A Active CN109069442B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010842414.4A Active CN111920785B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用

Country Status (13)

Country Link
US (2) US20190117568A1 (enExample)
EP (1) EP3443954A4 (enExample)
JP (2) JP7166929B2 (enExample)
KR (1) KR102410183B1 (enExample)
CN (2) CN111920785B (enExample)
AU (1) AU2017251548B2 (enExample)
BR (1) BR112018071208A2 (enExample)
EA (1) EA201892350A1 (enExample)
MX (1) MX394106B (enExample)
MY (1) MY204600A (enExample)
PH (1) PH12018502195A1 (enExample)
SG (2) SG11201809042SA (enExample)
WO (1) WO2017177966A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119345161A (zh) * 2024-12-25 2025-01-24 江苏长泰药业股份有限公司 一种丙酮酸钠雾化吸入制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026928A1 (en) * 2010-08-25 2012-03-01 Diacarta Llc Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891221A (en) * 1988-11-23 1990-01-02 Edward Shanborm Whole blood antiviral process and composition
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
CN101023953B (zh) * 2006-07-24 2010-05-12 南开大学 治疗支气管哮喘的组合物
CN101190232B (zh) * 2006-11-30 2011-08-17 江苏正大天晴药业股份有限公司 一种注射用异甘草酸镁冻干粉针剂及其制备方法
JP2008222682A (ja) * 2007-03-15 2008-09-25 Kumamoto Univ 線維化肺疾患治療薬、気道粘液分泌細胞過形成抑制剤および気道塞栓治療薬
CN101396368B (zh) * 2007-09-29 2010-12-01 江苏正大天晴药业股份有限公司 异甘草酸或其盐在制备治疗过敏性鼻炎药物中的应用
CN101669962A (zh) * 2009-09-18 2010-03-17 杭州市第六人民医院 复合甘草酸氨基酸注射液及其制备方法和应用
CN103156930A (zh) * 2011-12-19 2013-06-19 张亚军 一种含芍药和甘草提取物的呼吸道给药制剂
SG11201404522VA (en) 2012-03-13 2014-10-30 Respivert Ltd Crystalline pi3 kinase inhibitors
CN102920936A (zh) * 2012-09-17 2013-02-13 陈泉生 一种治疗呼吸道疾病的吸盐物及其制作方法
CN104042573A (zh) * 2014-06-03 2014-09-17 青岛市市立医院 一种异甘草酸镁冻干粉针剂及其制备方法
CN106237297A (zh) * 2016-08-30 2016-12-21 吉林紫鑫药业股份有限公司 一种用于治疗慢性支气管炎的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026928A1 (en) * 2010-08-25 2012-03-01 Diacarta Llc Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Glycyrrhizic Acid and 18β-Glycyrrhetinic Acid Inhibit Inflammation via PI3K/Akt/GSK3β Signaling and Glucocorticoid Receptor Activation;TZU-CHIEN KAO，et al;《J. Agric. Food Chem.》;20100714;第58卷;8623-8629 *

Also Published As

Publication number Publication date
JP7309791B2 (ja) 2023-07-18
CN111920785B (zh) 2022-05-20
MX2018012461A (es) 2019-09-18
US20200368158A1 (en) 2020-11-26
MY204600A (en) 2024-09-05
JP2021176903A (ja) 2021-11-11
EP3443954A1 (en) 2019-02-20
US11534398B2 (en) 2022-12-27
PH12018502195A1 (en) 2019-09-23
SG10202010192YA (en) 2020-11-27
BR112018071208A2 (pt) 2019-02-12
US20190117568A1 (en) 2019-04-25
AU2017251548B2 (en) 2022-02-17
EP3443954A4 (en) 2019-11-20
EA201892350A1 (ru) 2019-06-28
JP2019511556A (ja) 2019-04-25
CN109069442A (zh) 2018-12-21
KR102410183B1 (ko) 2022-06-17
WO2017177966A1 (zh) 2017-10-19
KR20180132143A (ko) 2018-12-11
AU2017251548A1 (en) 2018-11-15
JP7166929B2 (ja) 2022-11-08
SG11201809042SA (en) 2018-11-29
CN111920785A (zh) 2020-11-13
MX394106B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
JP2023086774A (ja) 乾燥粉末配合および使用方法
JPH09501700A (ja) 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用
US9861647B2 (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
WO2006036181A1 (en) Inhalable lidocaine formulation for treatment of asthma and for reducing the need for corticosteroids in asthmatic patients
CN114949183A (zh) 一种替尔泊肽粉雾剂及其制备方法
CN116635018A (zh) 吸入用药物组合物
WO2025002152A1 (zh) 一种新型薄荷脑桉树油镇咳喷雾剂及其应用
US20050053553A1 (en) Combined doses of formoterol and fluticasone
CN109069442B (zh) 异甘草酸或其盐的吸入制剂及其应用
JP2024531784A (ja) トブラマイシン吸入溶液を含む薬学的組立品及びその使用
JP2021176903A5 (enExample)
CN116763763A (zh) 一种司美格鲁肽吸入喷雾剂及其制备方法
CN115337311A (zh) 一种治疗呼吸系统疾病的组合物及其制备方法
WO2010009288A1 (en) Compositions and uses of antiviral active pharmaceutical agents
CN115137713B (zh) 一种两性霉素b雾化吸入制剂及其制备方法
HK1261173A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation
HK1261173B (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation
JPWO2017177966A5 (enExample)
WO2022166724A1 (zh) 一种福多司坦吸入用溶液制剂及其制备方法和用途
CN118903435A (zh) 复方药物制剂及其在医药上的应用
EA040563B1 (ru) Применение препарата для ингаляции на основе изоглицирризината магния для лечения заболеваний дыхательной системы
HK40060922B (zh) 一种包含妥布霉素吸入溶液的药物组件及其用途
WO2025093848A1 (en) Ensifentrine for treating bronchiectasis
WO2023206444A1 (zh) 一种曲前列尼尔软雾吸入剂
CN118542855A (zh) 一种吸入制剂、吸入装置及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261173

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Country or region after: China

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Country or region before: China